Land: Irland
Sprache: Englisch
Quelle: HPRA (Health Products Regulatory Authority)
EPROSARTAN MESYLATE
PCO Manufacturing
EPROSARTAN MESYLATE
400 Milligram
Film Coated Tablet
Product subject to prescription which may be renewed (B)
Withdrawn
2013-12-31
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Teveten 400mg Film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 400 mg eprosartan. Also contains lactose monohydrate. For a full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Film coated tablet. _Product imported from Greece:_ Pink capsule shaped, tablets with “SOLVAY” engraved on one side and “5044” on other. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Eprosartan is indicated for the treatment of essential hypertension. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The recommended dose is 600 mg eprosartan once daily. Achievement of maximal blood pressure reduction in most patients may take 2 to 3 weeks of treatment. Eprosartan may be used alone or in combination with other anti-hypertensives. In particular, addition of a thiazide-type diuretic such as hydrochlorothiazide or a calcium channel blocker such as sustained release nifedipine has been shown to have an additive effect with eprosartan. Eprosartan may be taken with or without food. Duration of treatment is not limited. GERIATRIC PATIENTS No dose adjustment is required in the elderly. DOSAGE IN HEPATICALLY IMPAIRED PATIENTS There is limited experience in patients with hepatic insufficiency (see Section 4.3 Contraindications). DOSAGE IN RENALLY IMPAIRED PATIENTS In patients with moderate or severe renal impairment (creatinine clearance < 60 ml/min), the daily dose should not exceed 600 mg. PAEDIATRIC PATIENTS Teveten is not recommended for use in children and adolescents due to lack of data on safety and efficacy. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 21/11/2012_ _CRN 2088153_ _page number: 1_ 4.3 CO Lesen Sie das vollständige Dokument